ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO239

Dripping Clues: Unveiling Diabetes Insipidus (DI), a Sneaky Presentation of Acute Myeloid Leukemia (AML)

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Rathi, Naveen, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
  • Kim, Isaac Inhwak, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
  • Gudsoorkar, Prakash Shashikant, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States

DI is a rare complication of AML seen with cytogenetic defects especially monosomy 7 & inversion 3. It can occur before or after diagnosis of AML, with or without brain imaging abnormalities. Here, we report a case of hypernatremia from DI in a patient with AML.

Case Description

A 68-year-old male with no medical history presented to ICU with altered mental status & polyuria (urine output > 5L/day), noted to have hemoglobin 6.8 g/dL. Led to AML diagnosis based on blood and bone marrow tests (Fig1). Karyotyping revealed inversion 3 [inv(3)(q21q26)] & monosomy 7. His serum sodium (SNa) was high on admission at 168 mEq/L. Over the past 3-4 weeks, he had increased urination. Further evaluations, including an MRI of the brain, showed no abnormalities. Urine osmolality was 168 mOSm/L (other metabolic tests were normal). Treatment with diamino D-arginine vasopressin (ddAVP) (2- 4 mcg/day) & free water boluses improved SNa (Fig2) and urine osmolality. Diagnosis of probable central DI based on the response to ddAVP, was made. With his mental status improving, he was switched to oral desmopressin (0.05 mg BID) and maintained stable SNa (140-145 mEq/L) upon discharge. Unfortunately, due to the non-response to his therapy for AML (decitabine), he was transitioned to hospice.


The pathogenesis of DI associated with AML (DI-AML) is not well understood. A possible mechanism is due to hypothalamic-pituitary infiltration of the leukemic cells or dysregulation of ADH due to dysthrombopoesis. Since approximately 90% of circulating ADH is associated with platelets, dysthrombopoesis in AML could lead to decreased levels and function of ADH. The 2 most common cytogenetic defects associated with DI-AML are monosomy 7 (80%) and inv-3 (46%). Patients with inv-3 and 50% involving monosomy 7 demonstrate activation of the MECOM [(MDS1 and EVI1 (ectopic virus integration site 1 protein homolog) complex] gene, leading to an increase in EVI-1 (a protein product). This disrupts the hypothalamic ADH secretion. We need more studies to prove an association between DI & AML. Our patient had features of CDI based on the evaluation & treatment response.